Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
Abstract
Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the development of effective antitumor immune responses is hampered by restricted immune cell infiltration and an immunosuppressive tumor microenvironment (TME). An immunotherapy that infiltrates and persists in the solid TME, while providing local, stable levels of therapeutic to activate or reinvigorate antitumor immunity could overcome these challenges faced by current immunotherapies.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2020
- Source ID
- 10.1136/jitc-2020-001356
Entities
People
- Amira D Davis
- Brooke M Prieskorn
- Chibawanye I Ene
- Courtney A Crane
- Courtney M Cowan
- Eric C Holland
- Harrison Chinn
- Jason K Yokoyama
- Jean S Campbell
- Kara W Moyes
- Katherine J Brempelis
- Kevin P. Labadie
- Kimberly S. Smythe
- Kole DeGolier
- Lisa R Matsumoto
- Michael C Jensen
- Nicole A P Lieberman
- Richard G. Ellenbogen
- Robert H. Pierce
- Sara K. Daniel
- Shannon A Kreuser
- Stephanie D Balcaitis
- Venu G Pillarisetty
- Virginia J Hoglund
Organizations
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke
- Stand Up to Cancer
- United States Army
- Washington Research Foundation